Tips, Trends & News You Can
RESEARCH SHOWS SPENDING SOME TIME IN THE SUN
UNPROTECTED COULD BE HEALTHY.
A number of recent studies touting the benefits of
sun exposure have caused mixed reactions in the medical community. While none conclude
that you should sit and bake in the sun, scientists have discovered the Vitamin
D we get from sunshine can help prevent and even treat some forms of cancer. Several
studies found it protects against lymphoma, cancers of the prostate, lung, colon,
and ironically, skin. Vitamin D also stifles abnormal cell growth, helps cells die
at the appropriate
time and curbs the formation of blood vessels that feed tumors.
Dr. Edward Giovannucci, a Harvard
University professor of medicine and nutrition, presented his findings at the Harvard
School of Public Health's 5th Annual Symposium in Nutrition. He says spending 15
minutes in the sun a few times a week without sunscreen is beneficial. The American
Cancer Society is reviewing its sun-protection guidelines.
Some doctors worry that patients will
use any excuse to get more sun exposure. Why not take supplements to reach adequate
levels of Vitamin D? Most supplements use an old form of the vitamin, D-2, which
is far less potent than D-3. Multivitamins contain only small doses of D-2 and include
vitamin A, which offsets many of D's benefits.
However, it's difficult to quantify
the value of vitamin D. There's a lack of consensus on how much vitamin D is necessary.
Most scientists believe adults need 1,000 IU of vitamin D/day, but Giovannucci's
research suggests 1,500 IU/day may be necessary to significantly curb cancer. Sunscreen
blocks Vitamin D production.
This is a good time to remind patients
that their eyes always need protection from the sun's rays, whether their skin
needs it or not.
EARNS PRESTIGIOUS GRANT.
ICO's "Vision of Hope" for Needy
Chicago healthcare program that serves uninsured, low-income adults, optometry serves
as the entry point. The Illinois College of Optometry's Vision of Hope Health Alliance
program takes a holistic approach to healthcare and addresses a common problem:
Lower income patients who often seek treatment for vision problems (because poor
vision interferes with daily activities) may not seek treatment for chronic health
"The Vision of Hope Health Alliance
takes down the barriers that limit entry into the health system," says Arol
Augsburger, O.D., president of ICO. "Under the program, optometry takes a leadership role in
detecting disease and facilitating treatment."
The Alliance includes a network of
community health and service agency
partners that include federally-qualified health centers, addiction treatment and
housing organizations. Caseworkers assist the patients in coordinating treatment
and follow-up care as well as providing critical services such as transportation
Recently, the program was awarded
a $500,000 grant from the Robert Wood Johnson foundation. With matching grants from
local sources, the program will receive $1million in funding over four years and
serve some 4,000 patients.
Dr. Augsburger says that the Alliance
is a response to the call set by the AOA's "Healthy Eyes, Healthy People," program.
"The Alliance isn't rhetoric," he says. "It establishes an effective healthcare
model that can be duplicated in other communities."
OWNER FOR THE SPECTACLE GROUP
Essilor to Acquire J&J's
Essilor announced that it has signed an agreement with
Johnson & Johnson to purchase its ophthalmic lens business, The Spectacle Lens
Group. That division developed the Definity brand of progressive lenses. Essilor
says that it will continue to market Definity and distribute the brand in the United
States. The transaction should close in the third quarter.
New CEO for Lighthouse. Lighthouse International
last month appointed Tara Cortes, R.N., Ph.D., its new president and chief executive
officer. Dr. Cortes previously served as Senior Vice President and Chief Nursing
Officer, Patient Care Operations, Bridgeport Hospital, Yale New Haven Health Care
Partnership enhances online shopping. Vision-Ease Lens's polycarbonate and glass
eyewear lenses will be featured on Eyefinity's Web site, according to a new partnership
the two companies formed.
Gerber Coburn, Essilor continue agreement. Gerber Coburn signed a three-year
distribution agreement with Essilor Instruments, a division of Essilor International.
Gerber Coburn will continue to distribute Essilor's lens finishing products exclusively
in North America and Australia and market-specific products worldwide. It will
also continue to work closely with Essilor Instruments to develop and manufacture
lens finishing systems.
First pair of wavefront-guided lenses introduced. Ophthonix Inc. sold its first
pair of iZon Wavefront Guided lenses, based on the company's Z-View technology.
In the article, "Strategic
Skill Builders: 10 Reasons to Fit Silicone Hydrogel Contact Lenses," in our May
issue, we incorrectly identified Noel Brennan as Mr. Brennan; he is Dr. Brennan.
OM regrets the error.
in the May issue, in the article "The Ins and Outs of Glaucoma Imaging Devices,"
the name of Heidelberg Engineering was misspelled. Again, OM regrets
VSP PROGRAM HELPS O.D.S
Program Hits Milestone
Vision One Loan Program has hit the $5 million mark in loans funded to private-practice
eye doctors who became practice owners. The program, funded by Vision Service Plan
(VSP) and administered by Vision One Credit Union, provides loans for optometrists
who lack the equity necessary to qualify for many small business loans.
The program is available in eight
states Idaho, Oregon, California, Ohio, Colorado, Indiana, Washington and
Texas. The funds may be used as equity support and payments may be deferred for
24 months to help offset transition risk and related potential cash shortfalls.
The program also provides loans for O.D.s buying into a private practice partnership
Additional information is available
presents its completely renovated Web site at santinelli.com. An expanded menu facilitates
navigation of the site, including tab choices to explore leasing options, provide
analysis worksheets and client services information. Visitors can request additional
information, offer comments and inquire about a free one-week product trial though
It's All in the Angle
to researchers at the University of Illinois at Chicago, knowing the correct angle
at which to hold your eye drop bottle when administering medication can save you
up to three bottles of medication a year. With compliance frequently a problem in
and medication cost often a serious issue for patients, researchers evaluated the
maximum number of drops obtained in once-a-day treatments in order to maximize patient
Researchers included 2.5 mL bottles
of Travatan, Xalatan and Lumigan in the study. Bottles were held vertically (90°),
at an angle (45°) and as horizontal as possible (0°). Travatan had 81,
103 and 102 drops respectively. Xalatan had 92, 90 and 65 drops per bottle, and
Lumigan 112, 105 and 78. Based on an average wholesale price of $62.19, $58.38 and
$62.10 for Travatan, Xalatan and Lumigan, respectively, the study found that patients
could save from $176 to $188
per year by holding Travatan at a 45° angle and Xalatan and Lumigan at 90°
over the eye. This translated to approximately two additional bottles a year for
Xalatan and three additional bottles for Travatan and Lumigan.
One researcher explained that the
number of drops in a bottle depends on the design and size of the bottle tip; the
viscosity, density and chemical composition of the liquid; and the way in which
a person holds and applies pressure to the bottle walls. And because the conjunctival
sack of the lower lid holds about 10 to 15 mL and an eye drop of solution contains
approximately 35 to 55 mL, a smaller drop is a more efficient drop, with less wasted
in run off. Allergan co-sponsored the study.
Contact Lens Ok'd for U.S.
FDA approved the Nike MAXSIGHT Sport-tinted Contact Lens by Bausch & Lomb for
daily wear for the correction of myopia and hyperopia. The polymacon lens is designed
to aid visual performance in athletic settings through its Light Architecture optics,
which filters specific wavelengths of light within the visual spectrum to enhance
key visual elements. Thus, the wearer can see an object such as a ball with greater
clarity, while sun glare is reduced.
B&L says it will launch the Nike
MAXSIGHT in the United States and Europe later this summer. It will be available
in two tints: gray-green, designed for sports played in bright sunlight, such as
gold, football, running and rugby; and amber, designed for fast-moving ball sports
played in variable light such as soccer, tennis, baseball and softball. B&L
codeveloped the contact lens with Nike Inc; B&L will manufacture it and market
it to eyecare professionals, while Nike will conduct consumer marketing activities.
Optometric Management, Issue: July 2005